Inmunoensayo ligado a enzimas (ELISA) a glicolípido fenólico -1 en pacientes con enfermedad de Hansen by Moreno, Luis Hernando & Alzate, Alberto
155
Colombia Médica                         Vol. 41 Nº 2, 2010 (Abril-Junio)
Enzyme-linked immunosorbent assay of phenolic glycolipid-I in patients
with Hansen’s disease
LUIS HERNANDO MORENO, MD1, ALBERTO ALZATE, MD, MSP2
SUMMARY
Introduction: Hansen’s disease or leprosy is a contagious-infection entity produced by the Hansen bacillus or
Mycobacterium leprae. The phenolic glycolipid is a special trisaccharide found in the bacillus cell wall and proved to be specific
and immunogenic species during M. leprae.
Objective: To determine the presence of the Hansen bacillus enzyme-linked immunoassay (ELISA) method glycolipid
phenolic I in a group of patients in Dermatology Consultation at the Valle del Cauca Health Services; these patients were
classified as cures or under watch according to criteria established by the World Health Organization (WHO).
Methodology: From the data base of the Dermatology Consultation at the Valle del Cauca Health Services, we studied
159 patients with Hansen’s disease who were tested with the enzyme-linked immunoassay (ELISA) with the phenolic glycolipid
I to cross reference information and observe if they were or were not positive to this test. A positive ELISA indicates the bacillus
is still present in the patient.
Results: As an important fact, we found that of 78 patients cured, when bearing in mind the monitoring period, 9 were
positive for the ELISA. When this period was discarded, 81 sick individuals were classified as cured according to WHO criteria
but the same 9 continued positive for ELISA.
Conclusion: It may be concluded that in spite of meeting WHO criteria, these patients still show presence of the bacillus
and the monitoring period is not required as a criterion to discharge a patient. We recommend adding to WHO criteria a negative
ELISA, to obtain additional information that helps to certify that a patient is or is not cured.
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Inmunoensayo ligado a enzimas (ELISA) a glicolípido fenólico -1 en pacientes con enfermedad de Hansen
RESUMEN
Introducción: La enfermedad de Hansen o lepra es una entidad infecto-contagiosa producida por el bacilo de Hansen o
Mycobacterium leprae. El glicolípido fenólico I es un trisacárido especial que se encuentra en la pared celular del bacilo y
ha demostrado ser específico de especie e inmunogénico durante la infección de M. leprae.
Objetivo: Determinar la presencia del bacilo de Hansen por el método de inmunoensayo ligado a enzimas (ELISA) a
glicolípido fenólico I en un grupo de pacientes del Consultorio Dermatológico del Servicio de Salud del Valle del Cauca
clasificados como curados o en vigilancia, según criterios preestablecidos por la Organización Mundial de la Salud (OMS).
Metodología: De la base de datos del Consultorio Dermatológico del Servicio de Salud del Valle del Cauca se estudiaron
en total 159 pacientes con enfermedad de Hansen a los cuales se les practicó examen de inmunoensayo ligado con enzimas
(ELISA) con el glicolípido fenólico I a fin de cruzar información y observar si eran o no positivos a esta prueba. El ELISA positivo
dice que el bacilo aún existe en el paciente.
Resultados: Se encontró como dato importante que de 78 pacientes curados, al tener en cuenta además el período de
vigilancia, 9 fueron positivos para el ELISA. Cuando se descartó este período, a 81 enfermos se les clasificó como curados
según criterios de la OMS pero siguieron positivos para ELISA los mismos 9.
Conclusión: Se concluye que a pesar de cumplir los criterios de la OMS, estos pacientes aún muestran presencia de bacilo
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y que el período de vigilancia no se necesita como criterio para
dar de alta a un paciente. Se recomienda agregar a los criterios
de la OMS el ELISA negativo, con el fin de tener una informa-
ción más que ayude a certificar que un paciente está curado
o no.
Palabras clave: ELISA; Hansen; Mycobacterium leprae;
Glicolipido fenólico; Lepra.
Hansen’s disease or leprosy is a contagious infection
pathology produced by an alcohol-acid resistant bacillus,
known as Hansen’s bacillus or Mycobacterium leprae.
M. leprae presents a triple coating rich in external
polysaccharides and a basal peptidoglycan that forms
the wall surrounding the cytoplasm. Peptidoglycans,
arabinogalactans, and mycolates significantly contribute
to the wall’s structural integrity, but do not contribute
major immunogenicity to the bacteria. Other glycolipids,
glycopeptidolipids, and trehalose containing lipooligo-
saccharides have been found to be active mycobacteria
components. The most notable of the glycolipid molecules
associated with the M. leprae cell wall is the phenolic
glycolipid I (pgl-I), a special trisaccharide that has
proven to be species specific and immunogenic during
M. leprae infection2.
Clinically, this entity is characterized by the diversity in
its presentation and its dependency on the conditions of the
host, above all from the immunologic point of view. It is
considered the main route of contamination of the upper
respiratory pathway, although we cannot discard the role
played in some instances by the sick skin. Currently,
leprosy is considered an entity whose principal reservoir is
the human being. The immunological conditions of the host
are essential in determining any of the known clinical
forms: undetermined, tuberculoid, dymorphous or
borderline, and lepromatous. The undetermined form is a
clinically and immunologically unstable condition of the
disease. The tuberculoid form is a stable aspect of the
disease; the smear is negative; the lepromin is positive.
Lepromatous leprosy is another stable form of the disease,
lepromin is negative, but there is presence of bacilli in the
smears. It is a contagious form of the disease. The
intermediate or borderline form is unstable and ends up in
one in any of the tuberculoid or lepromatous stable forms.
Mycobacteria are present, although not in the proportion
as in the lepromatous form; the Mitsuda reaction is generally
slightly positive. It is another contagious form of the
disease3.
Analysis of the circulating immune complex in
patients, above all those with phenolic glycolipid I as a
specific antigen and the role of macrophages has gained
importance in diverse research works and has led to
better understanding this disease3-10. Furthermore, a
correlation has been noted between the bacillary index
and the presence of the phenolic glycolipid I antigen in
serum of patients and it has been shown that levels of
antibodies towards this antigen diminish when treatment
starts11.
For the diagnosis of the disease and follow up of
patients, different laboratory methods are employed like
the smear, the biopsy, and the lepromin. A clinical exam
and a good clinical history are vitally important. However,
it is difficult to precisely define if a patient is or is not
cured, and if the bacillus persists in the patient’s organism
with the previous laboratory methods.
The enzyme-linked immune-absorbent assay
(ELISA) is a method that has acquired scientific
credibility and it is currently used to diagnose diverse
diseases like tuberculosis, dengue, rubella, and HIV,
among others. Brennan and Hunter9 managed to
characterize phenolic glycolipid I as a specific M.
leprae antigen. Seroepidemiologic studies in different
countries to diagnose the infection, have permitted
evaluating the ELISA test with a special antigen, phenolic
glycolipid I; works have been done with serum from both
paucibacillary and multibacillary patients, in whom
sensitivity has been between 82 and 100% for the
multibacillary and between 5 and 54.5% for the
paucibacillary with a global sensitivity between 43.8%
and 62.8%. Specificity in endemic and non-endemic
areas varied between 82% and 100%3.
With ELISA-type tests at antibody level in different
populations, it has been shown that:
· The serologic response to this antigen from individuals
infected is of IgM type12,13.
· The level of antibodies corresponds to the bacilli load
and increases, then, from the tuberculoid pole to the
lepromatous12,14.
· Almost all patients with the lepromatous form have
antibodies for this antigen14.
· Antibody levels diminish with chemeotherapy15.
· Seropositivity seems to precede the clinical mani-
festations of lepromatous patients15.
· In studies with household contacts of leprosy patients,
it has been found that 30% offer a positive response
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to these types of tests, but most do not develop the
disease16-18.
The Hansen ELISA is an indirect immune-enzymatic
test. It is worth noting that the titles are positive when the
antigen is present and we are dealing with a case of
leprosy; they are negative when there is no presence of
antigen and it may be excluded as a case. It has been
recommended that in the screening results the following
values should be used according to the ratio of the
fluorescence of the serum researched with respect to
the positive control serum: less than 0.3, negative; 0.3-
0.4, doubtful; 0.4-0.5, suspect; and greater than 0.5,
elevated19,20.
Through the current study, we sought to find the
correlation between the behavior of Hansen’s disease in
its different clinical states and its evolution with respect
to the ELISA method. We also compared this method to
those used traditionally to monitor patients such as the
smear and, above all, the clinical evaluation.
METHODS
Herein, we studied 159 patients with confirmed
diagnosis of Hansen’s disease. Respective and previously
defined samples were taken from the patients. Included
in the study were patients who were registered as sick
within the last three years, in addition to those who were
in the surveillance period and those who has been
discharged as cured. Three groups were formed; the
first group gathered those patients who were under
control within the last three years; the second group
included patients in the surveillance period, and the third
group took in those patients who had left the program as
cured. The study also included 20 patients with non-
lepromatous tuberculosis for the purpose of evaluating
the behavior of the Hansen ELISA technique against
the Koch bacillus as a microorganism different from M.
leprae and that could eventually have a crossed reaction
in this test.
The project was approved by the Ethics Committee
of the Faculty of Health at Universidad del Valle, Cali,
Colombia, and each patient signed an informed consent
prior to taking the blood sample. For the ELISA tests,
we used the UMELISA HANSEN equipment that
detects M. leprae IgM antibodies via fluorescence.
The data were recorded in an Excel data base and
they were analyzed by using the Epi Info program
version 6.0 to find the average, mode, and median for
each variable according to whether it is categorical or
continuous, estimate its standard error and deviation for
averages or proportions and, thus, calculate the reliability
intervals from each of the variables.
The risk factors to become ELISA positive were
analyzed on a four-cell table, where the dependent
variable is to continue positive for the phenolic glycolipid
I antigen after being considered cured according criteria
currently employed like: time of treatment for each
clinical form, negative smear, remission of symptoms
and medical signs, and regularity of treatment; also
analyzed was the surveillance time used.
The currently accepted cure criteria are:
· Disappearance of clinical lesions.
· Negative smear.
· Adequate treatment scheme according to clinical
form.
· Regularity during treatment.
Stemming from this definition of cure, we calculated
sensitivity. Since it is expected that the ELISA test
become the definite cure evidence, sensitivity and
specificity were analyzed, as well as the positive and
negative predictive values of the criteria used in this
study and the statistical significance was estimated in
agreement between both criteria (ELISA and «cure»)
through Cohen’s Kappa test.
RESULTS
We studied 159 patients with Hansen’s disease
(leprosy); 81 were under treatment and 78 were cured
according to clinical cure criteria, negative smear, and
adequate pharmacological treatment scheme for each
form of the disease. The surveillance period previously
used was also considered as additional criteria to
discharge patients and evaluate if it is recommended to
continue with the surveillance. Of the total number of
patients, 130 corresponded to the multibacillary form
(66 cured and 64 under treatment) and 29 to the
paucibacillary form (11 cured and 18 under treatment).
The 20 patients with tuberculosis were ELISA negative,
as expected (Table 1).
Of the 159 patients, 12 corresponded to dymorphous
leprosy (DL), 9 to undetermined (UL), 118 to lepromatous
(LL), and 20 to tuberculoid (TL); that is, 130 multibacillary
(MB) and 29 paucibacillary (PB). Patient ages ranged
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from 5 to 93 years of age (Table 2).
Of the 26 patients with elevated ELISA, 25 are LL
and 1 LD. With suspect ELISA of the total of 27, 23 are
LL, 1 LD, 2 LT, and 1 LI. Of the 106 with normal
ELISA, 70 are LL, 10 LD, 18 LT, and 8 LI. The
differences do not manage to be statistically significant
(p=0.05814026) because of the cells with very small
values or equal to zero.
Of the 26 patients with elevated ELISA, 18 show
negative smear and 8 are positive. With suspect ELISA
in 27 patients, 2 are positive and 25 negative. With a
normal ELISA test in 106 patients, 3 are positive for the
smear and 103 are negative. The statistical value is
p=0.00001724, significant statistical difference. It was
expected for the negative smears to also be negative
ELISA under 0.3 according to standard figures given by
previous studies (Table 3).
Of the 78 patients considered cured, 9 had elevated
ELISA and 14 had suspect ELISA. Only 55 of the 78
were negative. Of the patients with regular treatment,
28 had elevated or suspect ELISA and 47 had already
become negative through treatment.
DISCUSSION
Hansen’s disease (leprosy) continues to be a public
health problem in the world. Throughout the history of
humanity, many efforts have been made to better
understand this entity and reach its elimination and
subsequent eradication. This disease bears a historic
load that makes it feared by everyone. All scientific
research undertaken to understand it and treat it in the
best possible way are valid and should be considered.
This entity reveals immunological behavior that is special
and fascinating for any researcher. Since 1943, when
Table 1
Results of the ELISA test according to the clinical form of the disease
    ELISA
Clinical form Elevated     Negative        Suspect        Total
LD  1 10  1 12
LI  0   8  1  9
LL 25  70 23 118
LT   0  18  2   20
Total 26 106 27 159
Table 2
Results of the ELISA test according to the
smear result
                                    ELISA
  Smear      Elevated    Negative   Suspect  Total
  Positive  8 3  2 13
  Negative  18   103  25  146
  Total 26 106 27 159
Table 3
Results of the ELISA test according to the types of patients
                                                                                         ELISA
Type of patient          Elevated     Negative        Suspect      Total
Cured  9 55 14 78
Irregular treatment  2   1  0  3
Regular treatment 15  47 13 75
Monitored   0  3  0   3
Total 26 106 27 159
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diaminodiphenylsulfone (DDS) therapy was introduced,
and passing through the establishment of multidrug
therapy, the world’s medical and scientific community
has dreamt of eradicating this condition. Criteria have
been unified to define if a patient is cured or not of the
disease and what’s more, in many instances it is difficult
conduct an asserted diagnosis. It is common to find
relapses in individuals thought to be cured. For this
purpose, surveillance was instituted – initially for a
lifetime. Then, this surveillance time was reduced to two
years for paucibacillary patients and five years for
multibacillary patients; all this in agreement with diverse
clinical-epidemiological and bacteriological studies that
have been carried out. Currently, the conduct recom-
mended by the World Health Organization (WHO) and
the Colombian Ministry of Health is to consider as cured
every patient WHO:
· Receives adequate stipulated time of treatment for
diverse clinical forms.
· Is clinically cured.
· Has a negative smear; i.e., the patient is no longer
under surveillance.
However, there is no absolute certainty as to when
a patient is free from the bacillus. Clinical improvement,
time of treatment, adequate chemotherapy, and negative
smear are the methods currently employed to discharge
patients suffering or who suffered this disease. There
must be sufficient clear motives to discharge a leprosy
patient and consider such cured and avoid relapse as
much as possible. Because phenolic glycolipid-I is
characteristic of the M. leprae, it has permitted defining
the presence of the bacillus in organisms of patients or
possible patients. This definition is accomplished through
indirect techniques like the enzyme-linked immuno-
absorbent assay (ELISA) test.
In the current study, we found no statistical difference
in age or gender of patients and the greatest number of
these corresponded to multibacillary forms, i.e., those
considered contagious, which endorses every action
and/or recommendation for proper treatment of this
entity. We consider it important to suggest the execution
of the compared surveillance period, again as a cure
criterion, given that it is another motive that when added
to the ELISA results would furnish tools to aid in
deciding if a patient is free from the disease or does not
support the disease.
The most important aspect was to find patients who
considered themselves cured with high levels of ELISA,
suggesting that these were cases of sub-clinical patients
that should be watched closely or, ideally, receive
treatment until the test proves negative. ELISA is
proposed as an additional criterion, which if added to
those currently used would yield greater certainty on the
cure of the patient with Hansen’s disease and would
bring us closer to whether or not the patient is free from
the bacillus. Greater numbers of cure criteria available
will improve the patient’s welfare and that of the
community in general. Furthermore, we propose that the
values to define whether a title is high, suspect, doubtful,
or negative should be adjusted and we suggest that only
values lower than 0.40 be used for negative titles and
those greater than 0.40 for positive titles, which would
further simplify the analysis that added to pre-existing
criteria lead to precise conclusions and actions according
to the values obtained.
Furthermore, we suggest that individuals in contact
and those living with the patients -especially multibacillary
patients- undergo an ELISA test as part of its surveillance
to discover possible early or sub-clinical cases of the
disease and follow proper conduct. It is important to
highlight that a patient can remain positive for the
disease through multiple causes like irregularity in its
treatment, inadequate time of treatment, and lack of
clear criteria to establish if the patient is indeed cured
and can be discharged. Additionally, it is obligatory to
manifest the importance of the population follow up
(contacts and cohabitants) and the use of lepromin,
which along with the ELISA test would help in deciding
if an individual should or should not receive treatment or
should be merely observed with clinical and/or laboratory
follow up.
This research presents the following list of
conclusions:
· There is no precise method that tells exactly when a
leprosy patient is cured from the disease.
· To discharge a leprosy patient, there must be
abundant clinical motives and laboratory aids.
· ELISA is a laboratory test that helps to determine if
a patient is free or not from the Hansen bacillus.
· It is necessary to conduct surveillance again in the
follow up of patients with Hansen’s disease who
complete the treatment cycles.
· According to the results from the current research,
ELISA is recommended as a laboratory test for
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patients with leprosy who are going to be discharged
and who meet currently accepted requirements:
clinical cure, adequate treatment, compliance with
time of treatment, surveillance, and negative smear.
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